Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs

Published by Jordi Pardo on Sep 7, 2023

Disclaimer

Sponsors

Contact

Abstract

Language

en-ca

PICOS

PICO 2.1

Population
Down-titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
Intervention
Dose reduction
Comparator
continuation
Outcomes

PICO 2.2

Population
Down-titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
Intervention
Discontinuation
Comparator
continuation
Outcomes

PICO 2.3

Population
Adults with rheumatoid arthritis experiencing disease flare, and receiving DMARD therapy
Intervention
Glucocorticoids
Comparator
No glucocorticoids
Outcomes

PICO 2.4

Population
Adults with rheumatoid arthritis receiving DMARD therapy
Intervention
Glucocorticoid (GC) therapy as an adjunct to DMARD therapy
Comparator
DMARD therapy alone (placebo or no GC)
Outcomes

PICO 2.5

Population
Adults with rheumatoid arthritis initiating/adding/switching DMARD therapy (Comparison 1)
Intervention
Bridging GC + DMARD
Comparator
Placebo GC + (same) DMARD
Outcomes

PICO 2.6

Population
Adults with rheumatoid arthritis initiating/adding/switching DMARD therapy (Comparison 2)
Intervention
Bridging GC + DMARD
Comparator
(same) DMARD alone
Outcomes

PICO 2.7

Population
Adults with rheumatoid arthritis initiating/adding/switching DMARD therapy (Comparison 3)
Intervention
Bridging GC + DMARD + baseline GC
Comparator
(same) DMARD + baseline GC
Outcomes

PICO 2.8

Population
Adults with rheumatoid arthritis initiating/adding/switching DMARD therapy (Comparison 4)
Intervention
Parenteral bridging GC + DMARD
Comparator
Oral bridging GC + (same) DMARD
Outcomes